Trans-resveratrol

DIETARY_SUPPLEMENT8 trials

Conditions

AMDAge-related Macular DegenerationChoroidal NeovascularisationCognitive PerformanceCoronary Artery DiseaseDiabetes Mellitus, Type 2Endothelial DysfunctionEye Disease

Phase 1

Effects of Trans-Resveratrol in Endothelial Function in Hypertensive Patients

CompletedNCT02616822

Hospital Universitario Pedro ErnestoEndothelial Dysfunction

Start: 2013-01-31End: 2015-09-30Updated: 2015-11-30

Metabolism of Bioactive Dietary Polyphenol Preparation (BDPP)

CompletedNCT04421079

Icahn School of Medicine at Mount SinaiHealthy Control

Start: 2021-01-19End: 2024-12-02Updated: 2025-03-03

Phase 2

RESvEraTrol in Parkinson's Disease (RESET)

RecruitingNCT07592767

Georgetown UniversityParkinson's Disease

Start: 2026-09-17End: 2029-06-01Target: 30Updated: 2026-09-18

Unknown Phase

Cognitive Effects of 500mg Trans-resveratrol

CompletedNCT01794351

Northumbria UniversityCognitive Performance, Mood

Start: 2012-10-31End: 2012-12-31Updated: 2013-02-18

Pharmacokinetics of Trans-resveratrol Based Nutritional Supplement and Its Three Metabolites in Human Eyes and Blood

NCT02321176

Huazhong University of Science and TechnologyEye Disease

Start: 2014-03-31End: 2015-04-30Target: 20Updated: 2014-12-22

Resveratrol for Exudative Age-Related Macular Degeneration

TerminatedNCT02625376

Poitiers University HospitalAge-related Macular Degeneration, AMD, Choroidal Neovascularisation

Start: 2015-08-06End: 2016-11-09Updated: 2020-06-01

Short Interval Resveratrol Trial in Cardiovascular Surgery

Active, not recruitingNCT03762096

MaineHealthCoronary Artery Disease, Diabetes Mellitus, Type 2

Start: 2018-03-06End: 2026-12-31Target: 40Updated: 2025-04-03

Comparative Evaluation of Omega-3 and Resveratrol Supplementation in Periodontitis Patients

Active, not recruitingNCT07827391

Izmir Katip Celebi UniversityPeriodontitis

Start: 2025-01-01End: 2028-03-15Target: 60Updated: 2026-09-18

Trans-resveratrol

Sponsors

Conditions

Phase 1

Phase 2

Unknown Phase